Case Report

Frequency of HLA Antigens in Chronic Myelocytic Leukemia

Authors: JEANE P. HESTER MD, ROGER ROSSEN MD, JOSE TRUJILLO MD, KENNETH B. McCREDIE MB, ChB, FACP, FRACP, EMIL J. FREIREICH MD

Abstract

Histocompatibility antigen (HLA) phenotypes of 34 patients with Ph1+ chronic myelogenous leukemia (CML) were evaluated for association with HLA antigens. Two control populations were compared to the CML patients: 142 normal volunteer platelet donors, and 160 normal donors of granulocyte transfusions. HLA typing was done by lymphocyte microcytotoxicity tests for nine antigens on sublocus A and 15 antigens on sublocus B. HLA-B7 and HLA-B12 were decreased in CML patients compared to both platelet and granulocyte donors. There was increased frequency of HLA-A3 in patients (41%) as compared to controls (25% and 33%); HLA-B5 — patients = 20%; controls 8% and 6%; and HLA-BW17 — patients = 17%; controls = 6% and 3% (P = 0.01). Median survival was 24+ months and independent of HLA. HLA-B5 and HLA-BW17 were significantly increased in patients with CML compared to two normal control populations. No increase in HLA-B8 was seen. Decreased frequency of HLA-B7 and B12 was noted. The significance of these differences is being evaluated.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References